Turner Investments LLC Buys Shares of 3,000 Blueprint Medicines Corporation (BPMC)
Turner Investments LLC bought a new stake in shares of Blueprint Medicines Corporation (NASDAQ:BPMC) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 3,000 shares of the biotechnology company’s stock, valued at approximately $209,000.
Other institutional investors have also made changes to their positions in the company. Rockefeller Financial Services Inc. purchased a new stake in shares of Blueprint Medicines Corporation during the 3rd quarter valued at $160,000. Ameritas Investment Partners Inc. increased its position in shares of Blueprint Medicines Corporation by 68.9% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,410 shares of the biotechnology company’s stock valued at $173,000 after purchasing an additional 1,391 shares during the last quarter. Cambridge Investment Research Advisors Inc. purchased a new stake in shares of Blueprint Medicines Corporation during the 3rd quarter valued at $244,000. Fred Alger Management Inc. purchased a new stake in shares of Blueprint Medicines Corporation during the 2nd quarter valued at $203,000. Finally, SG Americas Securities LLC increased its position in shares of Blueprint Medicines Corporation by 23.3% during the 2nd quarter. SG Americas Securities LLC now owns 4,113 shares of the biotechnology company’s stock valued at $208,000 after purchasing an additional 778 shares during the last quarter. 91.99% of the stock is owned by hedge funds and other institutional investors.
In other Blueprint Medicines Corporation news, insider Kate Haviland sold 6,356 shares of Blueprint Medicines Corporation stock in a transaction dated Monday, September 18th. The stock was sold at an average price of $60.03, for a total transaction of $381,550.68. Following the completion of the transaction, the insider now owns 6,356 shares of the company’s stock, valued at approximately $381,550.68. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Anthony L. Boral sold 5,000 shares of Blueprint Medicines Corporation stock in a transaction dated Monday, November 6th. The shares were sold at an average price of $70.40, for a total value of $352,000.00. The disclosure for this sale can be found here. Insiders have sold a total of 54,305 shares of company stock valued at $3,671,782 in the last ninety days. Insiders own 3.40% of the company’s stock.
Several equities research analysts have recently issued reports on the company. Zacks Investment Research lowered Blueprint Medicines Corporation from a “hold” rating to a “sell” rating in a research report on Friday, August 4th. Canaccord Genuity set a $56.00 price objective on Blueprint Medicines Corporation and gave the stock a “buy” rating in a report on Wednesday, August 2nd. Cowen and Company reissued a “buy” rating on shares of Blueprint Medicines Corporation in a report on Friday, November 10th. Morgan Stanley lifted their price objective on Blueprint Medicines Corporation from $45.00 to $78.00 and gave the stock an “overweight” rating in a report on Monday, October 23rd. Finally, BTIG Research assumed coverage on Blueprint Medicines Corporation in a report on Friday, September 29th. They issued a “buy” rating and a $90.00 price objective for the company. One equities research analyst has rated the stock with a sell rating and ten have assigned a buy rating to the company’s stock. Blueprint Medicines Corporation has an average rating of “Buy” and an average target price of $70.47.
Shares of Blueprint Medicines Corporation (BPMC) traded up $0.86 on Tuesday, reaching $67.03. The company had a trading volume of 422,900 shares, compared to its average volume of 430,707. Blueprint Medicines Corporation has a 52 week low of $25.08 and a 52 week high of $74.42. The company has a quick ratio of 11.28, a current ratio of 11.28 and a debt-to-equity ratio of 0.02.
Blueprint Medicines Corporation (NASDAQ:BPMC) last announced its quarterly earnings data on Tuesday, October 31st. The biotechnology company reported ($0.96) earnings per share for the quarter, missing the consensus estimate of ($0.90) by ($0.06). The firm had revenue of $8.07 million during the quarter, compared to analysts’ expectations of $5.35 million. Blueprint Medicines Corporation had a negative return on equity of 43.11% and a negative net margin of 437.83%. The company’s revenue was up 31.0% compared to the same quarter last year. During the same period last year, the business posted ($0.62) EPS. sell-side analysts expect that Blueprint Medicines Corporation will post -3.74 earnings per share for the current year.
About Blueprint Medicines Corporation
Blueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. It focuses on crafting drug candidates that provide clinical responses to patients without adequate treatment options. It has developed a small molecule drug pipeline in cancer and a genetic disease.
Want to see what other hedge funds are holding BPMC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Blueprint Medicines Corporation (NASDAQ:BPMC).
Receive News & Stock Ratings for Blueprint Medicines Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines Corporation and related stocks with our FREE daily email newsletter.